Drug-related torsades de pointes in the isolated rabbit heart: Comparison of clofilium, d,l-sotalol, and erythromycin

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 3, 1998, Pages 425-434

  Eckardt, Lars ^a,c   Haverkamp, Wilhelm ^a   Mertens, Heinrich ^a   Johna, Robert ^a   Clague, Jonathan R ^b   Borggrefe, Martin ^a   Breithardt, Günter ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Clofilium; D,l Sotalol; Erythromycin; Hypokalemia; Isolated rabbit heart; Torsades de pointes

Indexed keywords

CLOFILIUM; ERYTHROMYCIN; SOTALOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; ELECTROCARDIOGRAM; ELECTROSTIMULATION THERAPY; HEART MUSCLE POTENTIAL; HEART VENTRICLE TACHYCARDIA; HYPOKALEMIA; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TORSADE DES POINTES;

ANIMALS; BRADYCARDIA; ELECTROCARDIOGRAPHY; ERYTHROMYCIN; HYPOKALEMIA; MALE; QUATERNARY AMMONIUM COMPOUNDS; RABBITS; SOTALOL; TORSADES DE POINTES;

EID: 0031663219     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199809000-00013     Document Type: Article

References (44)

1. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo - The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
2. Rogers WJ, Epstein AE, Arciniegas JG, et al. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33.
3. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-8.
4. Greene HL, Poole JE, Kudenchuk PJ, et al. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993;72:280-7.
5. Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995;6:920-36.
6. Eckardt L, Haverkamp W, Borggrefe M, et al. Experimental models of torsades de pointes. Cardiovasc Res 1998 (in press).
7. Franz MR, Cima R, Wang D, et al. Electrophysiological effects of myocardial stretch and mechanical determinants of stretch-activated arrhythmias. Circulation 1992;86:968-78.
8. Levine JH, Spear JF, Guarnieri T, et al. Cesium chloride-induced long QT syndrome: demonstration of afterdepolarizations and triggered activity in vivo. Circulation 1985;72:1092-103.
9. Arena JP, Kass RS. Block of heart potassium channels by clofilium and its tertiary analogs: relationship between drug structure and type of channel blocked. Mol Pharmacol 1988;34:60-6.
10. Castle NA. Selective inhibition of potassium currents in rat ventricle by clofilium and its tertiary homolog. J Pharmacol Exp Ther 1991;257:342-50.
11. Antzelevitch C, Sun Z-Q, Zhang Z-Q, et al. Cellular and ionic mechanisms underling erythromycin-induced long QT intervals and torsades de pointes. J Am Coll Cardiol 1996;28:1836-48.
12. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 1990;16:276-85.
13. Carlsson L, Abrahamsson C, Andersson B, et al. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res 1993;27:2186-93.
14. Carlsson L, Abrahamsson C, Drews L, et al. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization. Circulation 1992;85:1491-500.
15. Argentieri TM, Carroll MS, Sullivan ME. Cellular electrophysiological effects of the class III antiarrhythmic agents sematilide and clofilium on rabbit atrial tissues. J Cardiovasc Pharmacol 1991;18:167-74.
16. Haverkamp W, Martinez Rubio A, Hief C, et al. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia or survivors of cardiac arrest. J Am Coll Cardiol 1997;30:487-95.
17. Vos MA, Verduyn SC, Gorgels APM, et al. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation 1995;91:864-72.
18. Davy JM, Weissenburger J, Ertzbischoff O, et al. Sotalol-induced torsades de pointes in conscious dogs with atrioventricular block: role of hypokalaemia. Arch Mal Coeur Vaiss 1988;81:1117-24.
19. Dhein S, Muller A, Gerwin R, et al. Comparative study on the proarrhythmic effects of some antiarrhythmic agents. Circulation 1993;87:617-30.
20. Nattel S, Ranger S, Talajic M, et al. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 1990;89:235-8.
21. Haverkamp W, Shenasa M, Borggrefe M, et al. Torsade de pointes. In: Zipes DP, Jalife J, eds. Cardiac electrophysiology: from cell to bedside. 2nd ed. Philadelphia: WB Saunders, 1995:885-99.
22. Schoenenberger RA, Haefeli WE, Weiss P, et al. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes). Br Med J 1990;300:1375-6.
23. Paris DG, Parente TF, Bruschetta HR, et al. Torsades de pointes induced by erythromycin and terfenadine. Am J Emerg Med 1994;12:636-8.
24. Brandriss MW, Richardson WS, Barold SS. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review. Clin Infect Dis 1994;18:995-8.
25. Surawicz B, Lepeschkin E, Herrlich HC. Effect of potassium and calcium deficiency on the monophasic action potential, electrocardiogram and contractility of isolated rabbit hearts. Am J Physiol 1959;196:1302-7.
26. Zabel M, Hohnloser SH, Behrens S, et al. Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model. J Cardiovasc Electrophysiol 1997;8:1148-58.
27. Kr: implications for torsades de pointes and reverse use-dependence. Circulation 1996;93:407-11.
28. Buchanan LV, Kabell G, Branden MN, et al. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993;22:540-9.
29. Nattel S, Feder-Elituv R, Matthews T. Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs. J Am Coll Cardiol 1989;13:1190-4.
30. Johna R, Mertens H, Haverkamp W, et al. Clofilium in the isolated perfused rabbit heart: a new model to study proarrhythmia by class III antiarrhythmic drugs. Basic Res Cardiol 1998;93:127-35.
31. Freedman RA, Anderson KP, Green LS, et al. Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. Am J Cardiol 1987;59: 168-9.
32. Regan TJ, Khan MI, Oldewurtel H, et al. Antibiotic effect on myocardial K transport and the production of ventricular tachycardia. J Clin Invest 1969;48:68a.
33. Rubart M, Pressler ML, Pride HP, et al. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993;88:1832-44.
34. Daleau P, Lessard E, Groleau M, et al. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995;91:3010-6.
35. Oberg KC, Bauman JL. QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 1995;15:687-92.
36. Gitler B, Berger LS, Buffa SD. Torsades de pointes induced by erythromycin. Chest 1994;105:368-72.
37. Habbab M-DA, El Sherif N. Drug-induced torsades de pointes: role of early afterdepolarizations and dispersion of repolarization. Am J Med 1990;89:241-6.
38. Antzelevitch C, Sicouri S, Lukas A, et al. Regional differences in the electrophysiological of ventricular cells: physiological and clinical implications. In: Zipes DP, Jalife J, eds. Cardiac electrophysiology: from cell to bedside. 2nd ed. Philadelphia: WB Saunders, 1994:228-45.
39. Weissenburger J, Davy JM, Chezalviel F, et al. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. J Pharmacol Exp Thor 1991;259:871-83.
40. Keren A, Tzivoni D. Magnesium therapy in ventricular arrhythmias. PACE Pacing Clin Electrophysiol 1990;13:937-45.
41. Bailie DS, Inoue H, Kaseda S, et al. Magnesium suppression of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium in dogs. Circulation 1988;77:1395-402.
42. Davidenko JM, Cohen L, Goodrow R, et al. Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers: effects of stimulation rate, potassium, and magnesium. Circulation 1989;79:674-86.
43. Pogwizd SM. Nonreentrant mechanisms underlying spontaneous ventricular arrhythmias in a model of nonischemic heart failure in rabbits. Circulation 1995;92:1034-48.
44. El Sherif N, Caref EB, Yin H, et al. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome: tridimensional mapping of activation and recovery patterns. Circ Res 1996;79:474-92.